XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Cardiology Channel
subscribe to Cardiology newsletter

Latest Research : Cardiology

   DISCUSS   |   EMAIL   |   PRINT
PAS-Port for Heart To Get FDA Panel Review
Mar 11, 2005, 10:21, Reviewed by: Dr.

Cardica Inc.�s PAS-Port coronary proximal anastomosis device 510(k) will be reviewed by FDA�s Circulatory System Devices Panel April 22 in Gaithersburg, Md.

 
Cardica Inc.�s PAS-Port coronary proximal anastomosis device 510(k) will be reviewed by FDA�s Circulatory System Devices Panel April 22 in Gaithersburg, Md.

The PAS-Port system � an alternative to sutures � connects the proximal end of vein grafts to the aorta during coronary artery bypass graft (CABG) surgery. The device consists of an implantable connector and a delivery system to deploy the implant in the target vessel.

PAS-Port is CE-marked and distributed in Europe by Guidant, which has 20% stake in Cardica. More than 650,000 bypass surgeries are performed annually worldwide, according to the Redwood City, Calif. firm.

In March 2004, the Circulatory System Devices Panel convened to discuss clinical trial criteria for anastomosis devices, following concerns about underlying causes of adverse events associated with the products.

The panel recommended more stringent data requirements to support 510(k) submissions, including six-month angiographic follow-up for pivotal studies, an independent clinical events committee to address potential trial bias and 12-month post-market follow-up.

In addition to discussing the Cardica 510(k), panel members at the April 22 meeting will hear from the device center�s Office of Surveillance & Biometrics regarding the review process for condition-of-approval (CoA) studies. The advisory committee also will be briefed on devices it previously evaluated.

The Center for Devices & Radiological Health is shifting responsibility for CoA studies from the Office of Device Evaluation to the Office of Surveillance & Biometrics to ensure study completion. The center has said that publishing a guidance explaining CoA study requirements is a 2005 priority.
 

- Circulatory System Devices Panel
 

FDA Advisory Committee

 
Subscribe to Cardiology Newsletter
E-mail Address:

 

This meeting will be held April 22, 2005 at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m.

Related Cardiology News

Seven-point system gauges seriousness of heart failure in elderly
Uric acid levels closely related to hypertension in Blacks
American College of Cardiology announces new initiative to improve safety for patients with Acute Coronary Syndromes
Is TROPHY misleading?
Fortified orange juice decreases not only cholesterol but also CRP
Heart Disease: Blame it on genes!
Famotidine may help to slow progression of chronic heart failure
Atherothrombotic disease is not just a 'western' problem
Changing normal heart cells into pacemakers
Ilk gene underlies heart failure


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us